Symbio Natural Products Profile
Key Indicators
- Authorised Capital ₹ 4.50 M
as on 16-07-2024
- Paid Up Capital ₹ 0.18 M
as on 16-07-2024
- Company Age 7 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2022)
- Profit 80.92%
(FY 2022)
- Ebitda 85.64%
(FY 2022)
- Net Worth -4.55%
(FY 2022)
- Total Assets -2.28%
(FY 2022)
About Symbio Natural Products
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.50 M and a paid-up capital of Rs 0.18 M, as per Ministry of Corporate Affairs (MCA) records.
Akash Puranik, Abhijit Kale, and Salim Shaikh serve as directors at the Company.
- CIN/LLPIN
U74999TN2017PTC119375
- Company No.
119375
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Nov 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Symbio Natural Products?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Akash Puranik  | Director | 03-Nov-2017 | Current |
| Abhijit Kale | Director | 03-Nov-2017 | Current |
| Salim Shaikh | Director | 03-Nov-2017 | Current |
Financial Performance and Corporate Structure Insights of Symbio Natural Products.
Symbio Natural Products Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 80.92% increase in profit. The company's net worth dipped by a decrease of 4.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Symbio Natural Products?
In 2022, Symbio Natural Products had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Symbio Generrics India Private LimitedActive 13 years 6 monthsAkash Puranik and Salim Shaikh are mutual person
Vpl Chemicals Private LimitedActive 25 years 24 daysAkash Puranik and Salim Shaikh are mutual person
Sequent Penems Private LimitedActive 14 years 7 monthsAkash Puranik and Salim Shaikh are mutual person
Copernicium Pharmaceuticals Private LimitedActive 11 years 10 daysAkash Puranik and Salim Shaikh are mutual person
- Abhyansh Sugarcane Industries Private LimitedActive 2 years 3 months
Abhijit Kale is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Symbio Natural Products?
Unlock and access historical data on people associated with Symbio Natural Products, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Symbio Natural Products, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Symbio Natural Products's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
